Angiotensin II receptor blockers as antiglaucoma agents

Details Angiotensin II receptor blockers as antiglaucoma agents Angiotensin II receptor blockers as antiglaucoma agents

1991-05-06

1993-01-26

Griffin, Ronald W.

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

514 17, 514 15, 514912, 422 61, 435810, 436808, A61K 31475, A61K 3113, A61K 3154

Patent

active

051822644

ABSTRACT:
A method and composition for reducing and/or controlling elevated intraocular pressure, especially the elevated intraocular pressure associated with glaucoma, are disclosed in which an angiotensin II antagonist is administered to the eye.

REFERENCES:
patent: 3571404 (1973-08-01), Sipos et al.
patent: 3886134 (1975-05-01), Sipos et al.
patent: 3907762 (1975-09-01), Regoli et al.
patent: 3915948 (1975-10-01), Wille
patent: 3923769 (1975-12-01), Bumpus et al.
patent: 3923770 (1975-12-01), Bumpus et al.
patent: 3923771 (1975-12-01), Bumpus et al.
patent: 3925345 (1975-12-01), Bumpus et al.
patent: 3932624 (1976-01-01), Fulton
patent: 3976770 (1976-08-01), Bumpus et al.
patent: 4013791 (1977-03-01), Wissman et al.
patent: 4179433 (1979-12-01), Kisfaludy et al.
patent: 4204991 (1980-05-01), Hallinan et al.
patent: 4209442 (1980-06-01), Kisfaludy et al.
patent: 4330532 (1982-05-01), Nyeki et al.
patent: 4340598 (1982-07-01), Furukawa et al.
patent: 4355040 (1982-11-01), Furukawa et al.
patent: 4388304 (1983-06-01), Nyeki et al.
patent: 4444778 (1984-04-01), Coughlin
patent: 4515800 (1985-05-01), Cavero et al.
patent: 4517199 (1985-05-01), York, Jr.
patent: 4616012 (1986-10-01), Neustadt et al.
patent: 5036048 (1991-07-01), Watkins
Chem. Abstract, vol. 91, 1979, abstract 91:74909d.
Clinical Science and Molecular Medicine, (1976), 51, 403s-406s.
Ionistescu C., Rev. Chir., (oftalmol.), 26(2), 137-138 (with English translation).
The Merck Manual, 11th Edition, Rahway, N.J., 1966, pp. 484 and 511-515.
Stedman's Medical Dictionary, 22nd Edition; 1972, pp. 604, 643.
D. Regoli and J. R. Vane, A Sensitive Method for the Assay of Angiotension, Brit. J. Pharmacol., (1964), 23, pp. 351-359.
Remington's Pharmaceutical Sciences, Arthur Osol, (ed.), 16th Edition, Mack Publishing Co., Easton, Pa., 1980, p. 783.
Stedman's Medical Dictionary, 23rd Ed., The Williams & Wilkins Co., Baltimore, Md., 1976, pp. 586 and 203.
The Merck Index, 9th Ed., Merck & Co., Rahway, N.J., 1976, pp. 170 and 2899-2900.
Kul Bhushan Anand et al., Systemic Effects of Opthalmic Medication in the Elderly, Mar. 1988, pp. 134-136, New York State Journal of Medicine.
J. Cardivasc. Pharm., 5:1025, 1983.
Can. J. Physiol. Pharm., 57:763, 1979.
R. R. Luther et al., Renin Inhibitors: Specific Modulators of the Renin-Angiotensin System, Arzneim-Forsch./Drug Res., 39(1), No. 1, (1989), pp. 1-5.
Miguel A. Ondetti et al., Inhibition of the Renin-Angiotensin System. A New Approach to the Therapy of Hypertension, Journal of Medicinal Chemistry, vol. 24, No. 4, Apr. 1981, pp. 355-361.
Chiu et al., "Nonpeptide Angiotensin II Receptor Antagonists, VII. Cellular and Biochemical Pharmacology of DuP753, an Orally Active Antihypertensive Agent", The Journal of Pharmacology and Experimental Therapeutics, (1990), vol. 252, No. 2, pp. 711-718.
Wong et al., "Nonpetide Angiotensin II Receptor Antagonists, VIII. Characterization of Functional Antagonism Displayed by DuP753, and Orally Active Antihypertensive Agent", The Journal of Pharmacology and Experimental Therapeutics, (1990), vol. 252, No. 2, pp. 719-725.
Duncia et al., "The Discovery of Patent Nonpetide Angiotension II Receptor Antagonists: A New Class of Potent Antihypertensives", J. Med. Chem., 1990, 33, pp. 1312-1329.
Carini et al., "Nonpeptide Angiotensin II Receptor Antagonists: N-[(Benzyloxy)benzyl] imidazoles and Related Compounds Potent Antipertensives", J. Med. Chem., 1990, 33, pp. 1330-1336.
P. A. Khairallah et al., J. Med. Chem., 13, 181 (1970).
Clin. Sci., 57:71, 1979.
Endocrinology, 107(5):1305, 1980.
Am. Journal Physiol., 236(3):F252, 1976.
Clin. Sci. Mol. Med., 51:385s, 1976.
Am. J. Physiol., 236(3):F252, 1976.
Clin. Sci. Mol. Med., 51:385s, 1976.
J. Cardiovasc. Pharm., 5:1025, 1983.
Life Sci., 34:317, 1983.
Can. J. Physiol. Pharm., 57:121, 1979.
J. Pharm. Pharmacol., 32:232, 1980.
J. Med. Chem., 22(9):1147, 1979.
J. Med. Chem., 20(2):253, 1977.
J. Med. Chem., 19(2):244, 1976.
J. Med. Chem., 13:181, 1970.
Circ. Res., 29:664, 1971.
Circ. Res., 46:720, 1980.
Proc. Nat'l Acad. Sci. U.S.A., 67:1624, 1970.
J. Med. Chem., 20:898, 1977.
Cir. Res., 31:862, 1972.
Chemical Abstracts, vol. 95, Abstract No. 175775V.
Chemical Abstracts, vol. 89, Abstract No. 24819n.
Chemical Abstracts, vol. 91, Abstract No. 39880r.
Chemical Abstracts, vol. 91, Abstract No. 74909d.
Chemical Abstracts, vol. 95, Abstract No. 7777d.
Weiner, N., The Pharmaceutical Basis of Therapeutics, (ed. A. G. Goodman, L. S. Goodman, A. Gilman), Macmillan Publishing, New York, 1980, 6th Ed., pp. 188-197.
Physicians Desk Reference for Opthalmology, 11th Ed., 1983, p. 126.

Affiliated with

Also associated with

Rating

Angiotensin II receptor blockers as antiglaucoma agents does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Angiotensin II receptor blockers as antiglaucoma agents, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Angiotensin II receptor blockers as antiglaucoma agents will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-1412706